Literature DB >> 2829028

Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis.

S Jacobson1, C S Raine, E S Mingioli, D E McFarlin.   

Abstract

Tropical spastic paraparesis (TSP) is a slowly progressive myelopathy associated with increased serum and cerebrospinal fluid antibodies to the human T-lymphotropic retrovirus type I (HTLV-I) (ref. 1), and has been observed in many regions of the world. A similar condition known as HTLV-I-associated myelopathy occurs in the Kagoshima prefecture of Japan. Recent but controversial reports suggest involvement of virus related to HTLV-I in multiple sclerosis. Magnetic resonance imaging and electrophysiological studies indicate that TSP lesions are like multiple sclerosis in that they are disseminated throughout the nervous system. Complete virus from patients with TSP has proved difficult to isolate using techniques successful in adult T-cell leukaemia cases associated with HTLV-I. Here we report the isolation of an HTLV-I-like virus from T-cell lines derived from the peripheral blood and cerebrospinal fluid of TSP patients. The monoclonal antibody OKT3 was used to generate non-transformed T-cell lines that express HTLV-I antigens. Infectious virus was demonstrated by co-cultivation and complete, replicating virions were visualized ultrastructurally.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829028     DOI: 10.1038/331540a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  79 in total

1.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis.

Authors:  D A Hafler
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 3.  RNA polymerase III transcription: its control by tumor suppressors and its deregulation by transforming agents.

Authors:  T R Brown; P H Scott; T Stein; A G Winter; R J White
Journal:  Gene Expr       Date:  2000

4.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

5.  Infectivity of chimeric human T-cell leukemia virus type I molecular clones assessed by naked DNA inoculation.

Authors:  T M Zhao; M A Robinson; F S Bowers; T J Kindt
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

6.  Search for human T-cell leukemia virus type I (HTLV-I) proviral sequences by polymerase chain reaction in the central nervous system tissue of HTLV-I-associated myelopathy.

Authors:  Y Ohara; Y Iwasaki; S Izumo; I Kobayashi; A Yoshioka
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Transcriptional activation of RNA polymerase III-dependent genes by the human T-cell leukemia virus type 1 tax protein.

Authors:  J M Gottesfeld; D L Johnson; J K Nyborg
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 8.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  HTLV-1 seroprevalence in AIDS patients and in HIV-1 seropositive and seronegative subjects at risk for AIDS in northern Italy.

Authors:  N Manca; A Caruso; C Bonfanti; E Savoldi; R Li Vigni; F Pirali; P L Sapelli; A Turano
Journal:  Eur J Epidemiol       Date:  1989-03       Impact factor: 8.082

10.  T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones.

Authors:  K W Wucherpfennig; P Höllsberg; J H Richardson; D Benjamin; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.